c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
Open Access
- 1 February 2015
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (2) , e976077
Abstract
Background: The expression of c-met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-beta production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLA-DR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-b production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.Keywords
This publication has 31 references indexed in Scilit:
- Heat Shock Protein 90 Inhibitors Repress Latent Membrane Protein 1 (LMP1) Expression and Proliferation of Epstein-Barr Virus-Positive Natural Killer Cell LymphomaPLOS ONE, 2013
- Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified PeptidesClinical Cancer Research, 2012
- Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancerJournal of Translational Medicine, 2011
- The Role of Autophagy in Cancer: Therapeutic ImplicationsMolecular Cancer Therapeutics, 2011
- HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell CancerClinical Cancer Research, 2009
- Efficient Cross-presentation Depends on Autophagy in Tumor CellsCancer Research, 2008
- Combined Clinical Trial Results of a HER2/neu(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2008
- Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-LymphocytesClinical Cancer Research, 2004
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 Journal of Experimental Medicine, 2003
- CD56+ NK lymphomas:clinicopathological features and prognosisBritish Journal of Haematology, 1997